Get started
Author

Isabelle Cojean Zelek

ORCID: 0009-0007-1143-7872
Observed ORCID: 0009-0007-1143-7872
OpenAlex ID: A5122332814
ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial
2026 · Guillaume Beinse, Valerie Taly, et al. · Clinical Cancer Research · 2
ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial
2026 · Félix Blanc-Durand, Catherine Genestie, et al. · Clinical Cancer Research · 2
Supplementary Table S1 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial
2026 · Guillaume Beinse, Valerie Taly, et al.
Supplementary Figure S3 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial
2026 · Guillaume Beinse, Valerie Taly, et al.
Supplementary Figure S2 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial
2026 · Guillaume Beinse, Valerie Taly, et al.
Supplementary Figure S8 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial
2026 · Guillaume Beinse, Valerie Taly, et al.
Supplementary Figure S6 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial
2026 · Guillaume Beinse, Valerie Taly, et al.
Supplementary Figure S7 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial
2026 · Guillaume Beinse, Valerie Taly, et al.
Supplementary Figure S1 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial
2026 · Guillaume Beinse, Valerie Taly, et al.
Supplementary Figure S5 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial
2026 · Guillaume Beinse, Valerie Taly, et al.
Supplementary Figure S4 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial
2026 · Guillaume Beinse, Valerie Taly, et al.
Data from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial
2026 · Guillaume Beinse, Valerie Taly, et al.
Supplementary Figure S9 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial
2026 · Guillaume Beinse, Valerie Taly, et al.
Data from ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial
2026 · Félix Blanc-Durand, Catherine Genestie, et al.
Supplementary Table S1 from ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial
2026 · Félix Blanc-Durand, Catherine Genestie, et al.
Works count: 15
Citation count: 4
H-index: 2
I10-index:
Year
Topic
Type